Company news
Delcath Systems, Inc. (NASDAQ:DCTH) news
Every Delcath Systems, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference
July 28, 2026
Delcath Systems to Host Second Quarter 2026 Earnings Call
July 23, 2026
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
July 9, 2026
Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts
May 26, 2026
Delcath Systems Reports First Quarter 2026 Results and Business Highlights
May 7, 2026
Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast C...
May 7, 2026
Delcath Systems to Host First Quarter 2026 Earnings Call
April 23, 2026
Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Ther...
April 6, 2026
Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting
April 1, 2026
Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology
March 3, 2026
Delcath Systems Reports Fourth Quarter and Full Year 2025 Results
February 26, 2026
Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call
February 12, 2026
Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
January 27, 2026
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 21, 2026
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
January 9, 2026
Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients wi...
December 31, 2025
Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastati...
December 3, 2025
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program
November 20, 2025
Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma
November 18, 2025
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Te...
November 13, 2025
Delcath Systems to Participate in Upcoming Investor Conferences
November 6, 2025
Delcath Systems Reports Third Quarter 2025 Results and Business Highlights
November 4, 2025
Delcath Systems to Host Third Quarter 2025 Earnings Call
October 21, 2025
Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results
October 18, 2025
Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint
October 18, 2025
As part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executives
October 9, 2025
Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress
September 22, 2025
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer
August 19, 2025
Delcath Systems Reports Second Quarter 2025 Results and Business Highlights
August 6, 2025
Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference
July 29, 2025
Delcath Systems to Host Second Quarter 2025 Earnings Call
July 23, 2025
Delcath Systems Issues Full Year 2025 Guidance
May 22, 2025
Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference
May 15, 2025
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 9, 2025
Delcath Systems Reports First Quarter 2025 Results and Business Highlights
May 8, 2025
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
April 28, 2025
Delcath Systems to Host First Quarter 2025 Earnings Call
April 24, 2025
Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma
April 9, 2025
Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference
March 24, 2025
Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 14, 2025
Delcath Systems Reports Fourth Quarter and Full Year 2024 Results
March 6, 2025
Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call
February 20, 2025
Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uv...
February 14, 2025
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
January 13, 2025
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 3, 2025
Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises
December 30, 2024
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal...
December 2, 2024
Delcath Systems Reports Third Quarter 2024 Results and Business Highlights
November 8, 2024
Delcath Systems to Host Third Quarter 2024 Earnings Call
October 25, 2024
Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results
October 17, 2024